Latest Manufacturing Processes News

Archer Materials has achieved critical milestones in its carbon-based quantum technology, including wafer-scale synthesis and reproducible device performance, setting the stage for operational qubits by mid-2026.

Aurora Labs has secured over A$900,000 in contracts with the Australian Defence Force, pushing forward its advanced propulsion systems and additive manufacturing capabilities. A strategic partnership with Sovereign Propulsion Systems aims to integrate these innovations into next-generation unmanned aerial systems.

Mesoblast Limited reports a robust 66% increase in Ryoncil revenues for Q2 2025, driven by strong market adoption and new Medicare reimbursement codes.

NOVONIX has delivered its first commercial-grade synthetic graphite sample at mass production scale, marking a key step toward expanding its battery and industrial materials footprint.

ClearVue Technologies has unveiled its Gen3 Solar Vision Glass, achieving a 66% increase in energy output and a 50% reduction in production time and costs, validated by independent testing. This breakthrough positions the company for accelerated commercial adoption in solar-integrated building materials.

Cambium Bio has struck a licensing deal with Keke Medtech to commercialise its fibrin biologic in dental applications, unlocking new markets and non-dilutive funding.

Papyrus Australia has marked significant progress in July 2025 with successful testing at its Rapid Prototyping facility and advancing plans for a commercial production site, while also writing down key investments.

Nanollose Limited reported a $1.43 million loss for FY2025 while progressing pilot production of innovative biomaterials and strengthening its balance sheet with a $2.1 million capital raise. The company appointed a new CEO to drive commercialisation efforts in FY2026.

InhaleRx has secured ethics approval to begin a Phase 1 clinical trial of IRX-616a, a synthetic cannabidiol inhaler aimed at providing fast relief for panic disorder. The fully funded study will assess safety and pharmacokinetics in healthy volunteers.

Weebit Nano has reported a remarkable 300% revenue increase to $4.4 million in FY25, driven by expanding licensing deals for its advanced ReRAM technology.

Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.

Mayfield Group Holdings Ltd has reported a landmark financial year with revenues soaring nearly 38% and profits climbing over 32%, driven by strong demand in Data Centres and AI infrastructure sectors.